Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "SUIT-011"

From Bioblast
Β 
(40 intermediate revisions by 7 users not shown)
Line 1: Line 1:
{{MitoPedia
{{MitoPedia
|abbr=NS(GM)
|abbr=GM+S_OXPHOS+Rot_ET
|description=[[File:1GM;2D;3S;4U;5Rot-.png|300px]]
|description=[[File:1GM;2D;3S;4U;5Rot-.png|400px|SUIT-011]]
|info='''A''' [[MiPNet12.23 FibreRespiration]]
|info='''A: Maximum mitochondrial respiratory capacity ([[Oxidative phosphorylation|OXPHOS]] with [[NS-pathway control state|NS substrates]]) and coupling/pathway control'''
}}
}}
{{MitoPedia concepts
::: '''[[SUIT protocol pattern]]:''' 1GM;2D;2c;3S;4U;5Rot-
|mitopedia concept=SUIT protocol, SUIT A
Β 
}}
The SUIT-011 protocols are designed to study physiologically relevant maximum mitochondrial respiratory capacity ([[Oxidative phosphorylation|OXPHOS]] with [[NS-pathway control state|NS substrates]]) and coupling/pathway control states. SUIT-011 gives information of the linear coupling control ([[LEAK respiration|''L'']]-[[Oxidative phosphorylation| ''P'']]) with NADH linked-substrates ([[GM-pathway control state|GM]]). GM and PM yield practically identical fluxes in human skeletal muscle fibres. However, PM is the superior alternative to GM, since the fractions of the N-pathway is lower and of the S-pathway is higher with GM compared to PM. PM, therefore, yields a more sensitive assay for the diagnosis of injuries in the N-linked pathway (compare [[SUIT-001]] and [[SUIT-004]]). Moreover, SUIT-011 allows the evaluation of the coupling-control state ([[Oxidative phosphorylation|''P'']]-[[ET capacity| ''E'']]) with NADH and succinate linked-substrates ([[NS-pathway control state|NS]]) and the pathway control in OXPHOS ([[NS-pathway control state|NS]]) and ET state ([[NS-pathway control state|NS]] and [[Succinate pathway control state|S]]). SUIT-011 can be extended with the CIV assay module.
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' NS(GM)
Β 
::: '''[[SUIT protocol pattern]]:''' diametral
Β 
__TOC__
Communicated by [[Doerrier C]] and [[Gnaiger E]] (last update 2019-06-05)
Β 
== Specific SUIT protocols ==
[[File:1GM;2D;2c;3S;4U;5Rot;6Ama.png|400px]]
[[File:D024_O2_traces.png|400px]]
*Β  [[SUIT-011 O2 pfi D024]] for permeabilized fibers
Β 
{{Template:SUIT-011}}
Β 
== Strengths and limitations ==
Β 
:::* Comparison of GM- with PM-capacity yields important information on N-pathway respiratory control upstream of CI ([[Lemieux 2017 Sci Rep|Lemieux ''et al.'' 2017]]; [[Votion 2012 PLoS One|Votion ''et al.'' 2012]]).
:::* A succinate concentration of >10 mM may be required for saturating SE capacity.
:::* Rox might be inhibited slightly further by inhibition of CIV by cyanide (KCN; 1 ΞΌM). But cyanide inhibits not only CIV, but also catalase and other oxygenases involved in ROX.
:::+ NS-OXPHOS capacity provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
:::+ Glutamate is easier to prepare compared to pyruvate.
:::+ Application of the cytochrome ''c'' test early in the protocol ensures comparability of all states in case of any effect of ''c''.
:::+ Reasonable duration of the experiment.
:::- GM and PM yield typically identical fluxes in human skeletal muscle fibres. However, PM is the superior alternative to GM: the fraction of the N-pathway is lower and of the S-pathway is higher with GM compared to PM (GM<sub>''P''</sub> is inhibited by the CII inhibitor malonic acid to a larger extent than PM<sub>''P''</sub>). PM, therefore, yields a more sensitive assay for the diagnosis of injuries in the N-pathway, since an impairment of N-pathway capacity can be compensated partially by activation of the S-pathway. This is a disadvantage compared to SUIT-004 and SUIT-008 for diagnosis of N-capacity.
:::- To detect an additive effect of P after GM<sub>''P''</sub>, pyruvate would have to be added as step 3 (before S). However, inhibition of respiration was observed after titration of P (5 mM) in horse skeletal muscle fibres (Votion et al 2012), which was not the case when P was titrated in steps of 1 mM.
:::- When evaluating the additive effect of the N- and S-pathway, it has to be considered that NS<sub>''P''</sub>- and NS<sub>''E''</sub>-capacities can only be compared with N<sub>''P''</sub>- and S<sub>''E''</sub>-capacities. This is not a problem when NS<sub>''P''</sub> = NS<sub>''E''</sub> (Gnaiger 2009). Otherwise, it may be assumed that S<sub>''P''</sub> = S<sub>''E''</sub> (Votion et al 2012), such that NS<sub>''P''</sub> can be compared with N<sub>''P''</sub> + S<sub>''P''</sub>. SUIT-004 should be chosen for the additive effect in the ET-state.
:::- ''Rox'' may be lower in substrate states earlier in the SUIT protocol. Therefore, this ''Rox'' measurement is frequently taken as a methodological control rather than as the final basis of ''Rox'' correction of mitochondrial respiration (mt).
:::- Careful washing is required after the experiment to avoid carry-over of inhibitors and uncoupler.
:::- CIV activity is not measured, to save experimental time.
Β 
Β 
== Compare SUIT protocols ==
Β 
::::* GM and PM yield typically identical fluxes in human skeletal muscle fibres.
::::* [[SUIT-004]] 1PM;2D;3U;4S;5Rot-: SUIT-004 allows the evaluation of the linear coupling control ([[LEAK respiration|''L'']]-[[Oxidative phosphorylation| ''P'']]) with PM (instead of GM) as NADH linked-substrates. Moreover, in SUIT-004 the linear coupling control from [[Oxidative phosphorylation| ''P'']] to [[ET capacity| ''E'']] (with PM) and the ET-pathway state in[[NS-pathway control state| NS-]] and [[Succinate pathway control state| S-pathways]] can be assessed.
::::* [[SUIT-008]] 1PM;2D;3G;4S;5U;6Rot-: SUIT-008 protocols are designed to assess the additivity between the [[NADH_Electron_transfer-pathway_state| N-]] and [[Succinate pathway control state| S-pathway]] in the [[Q-junction]], providing a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
::::* [[SUIT-001]] 1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-: [[SUIT reference protocol]] 1 (RP1)gives information of the linear coupling control ([[LEAK respiration|''L'']]-[[Oxidative phosphorylation| ''P'']]-[[ET capacity| ''E'']]) with NADH linked-substrates ([[PM-pathway control state|PM]]). Moreover, the pathway control in ET state ([[NADH_Electron_transfer-pathway_state|N]], [[NS-pathway control state| NS]], [[FNS]], [[Succinate pathway control state| S]] and [[SGp-pathway control state| SGp]] pathways) can be evaluated by using this SUIT protocol.
::::* [[SUIT-028]]: PGM as NADH linked-substrates.
Β 
== References ==
== References ==
{{#ask:[[Category:Publications]] [[Additional label::SUIT-011]]
{{#ask:[[Category:Publications]] [[Instrument and method::O2k-Protocol]] [[Additional label::SUIT-011]]
|?Was published in year=Year
|?Was published in year=Year
|?Has title=Reference
|?Has title=Reference
Line 22: Line 57:
}}
}}


Β 
{{MitoPedia concepts
== SUIT-011 ==
|mitopedia concept=MiP concept, SUIT protocol, Recommended
[[File:1GM;2D;2c;3S;4U;5Rot-.png|300px]] 1GM;2D;2c;3S;4U;5Rot;6Ama
}}
::: '''SUIT states:''' 1-2[[GM]](LPc) 3-4[[GMS]](PE) 5[[S]] 6[[ROX]]
{{MitoPedia methods
Β 
|mitopedia method=Respirometry
{| class="wikitable" border="1"
}}
|-
! Step
! Respiratory state
! Pathway control
! ET-Complex entry into Q-junction
! Comment
Β 
|-
| 1GM
| [[GM]]<sub>''L''</sub>
| [[N]]
| CI
| LEAK state with type N substrates, N<sub>''L''</sub>: Non-phosphorylating resting state with NADH-linked (type N) substrates glutamate&malate (GM; without adenalytes; CI-linked pathway to Q). ''See'' 2D.
Β 
Β 
|-
| 2D
| [[GM]]<sub>''P''</sub>
| [[N]]
| CI
Β 
| OXPHOS capacity with type N substrates, NP: Respiratory capacity in the active coupled state (GM with ADP). GM and PM yield practically identical fluxes in human skeletal muscle fibres. However, PM is the superior alternative to GM, since the fractions of the N-pathway is lower and of the S-pathway is higher with GM compared to PM. PM, therefore, yields a more sensitive assay for the diagnosis of injuries in the N-linked (CI-linked) pathway. ''Compare'' [[1PM;2D;3U;4S;5Rot-]] and [[1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp- |1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp- ]].
Β 
|-
| D(c)
| [[GM]]c<sub>''P''</sub>
| [[N]]
| CI
Β 
| Cytochrome c test for quality control of the integrity of the outer mitochondrial membrane (loss of cytochrome c is indicated by a stimulation of respiration). Cytochrome ''c'' added immediately after the earliest ADP-activation step. Application of the cytochrome ''c'' test early in the protocol ensures comparability of all states in case of any effect of ''c'' ([[Gnaiger 2007 MitoPathways]]).
Β 
|-
| 3S
| [[GMS]]<sub>''P''</sub>
| [[NS]]
| CI&II
| OXPHOS capacity with type NS substrates (CI<small>&</small>II-linked pathway to Q), NS<sub>''P''</sub>: Respiratory stimulation by convergent electron flow through Complexes I<small>&</small>II at the Q-junction, in the coupled state after further addition of succinate (S), as an estimate of OXPHOS capacity with reconstitution of the TCA cycle ([[Gnaiger 2009 Int J Biochem Cell Biol]]).
Β 
|-
| 4U
| [[GMS]]<sub>''E''</sub>
| [[NS]]
| CI&II
| Electron transfer-pathway (ET-pathway) capacity with type NS substrates, NS<sub>''E''</sub>: Uncoupling by CCP or FCCP titration (avoiding inhibition by high uncoupler concentrations), as a test for limitation of OXPHOS relative to ET capacity by the phosphorylation system. Limitation: The additive effect of N+S measured separately compared to the combined NS pathway cannot be evaluated in the same coupling state. With N<sub>''P''</sub>, NS<sub>''P''</sub>, NS<sub>''E''</sub>, and S<sub>''E''</sub>. IfΒ  independent information is available on S<sub>''P''</sub> = S<sub>''E''</sub>, the additivity can be calculated for the OXPHOS state.
Β 
|-
| 5Rot
| [[S]]<sub>''E''</sub>
| [[S]]
| CII
Β 
| ET capacity with type S (CII) substrate, S<sub>''E''</sub>: ET capacity with succinate, after blocking Complex I with rotenone. Limitation: A succinate concentration of >10 mM may be required for saturating S<sub>''E''</sub> capacity.
Β 
|-
| 6Ama
|
| ROX
| ROX
| Residual oxygen consumption (ROX) due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). ROX may be lower in substrate states earlier in the SUIT protocol. Therefore, this ROX measurement is frequently taken as a methodological control rather than as the final basis of ROX correction of mitochondrial respiration (mt).
Β 
|}
Β 
== 1GM;2D;3S;3c;4U;5Rot- ==
[[File:1GM;2D;3S;3c;4U;5Rot-.jpg|300px]] 1GM;2D;3S;3c;4U;5Rot;6Ama
::: '''SUIT states:''' 1-2[[GM]](LP) 3-4[[GMS]](PcE) 5[[S]] 6[[ROX]]

Latest revision as of 15:35, 8 June 2020


high-resolution terminology - matching measurements at high-resolution


SUIT-011

Description

SUIT-011

Abbreviation: GM+S_OXPHOS+Rot_ET

Reference: A: Maximum mitochondrial respiratory capacity (OXPHOS with NS substrates) and coupling/pathway control

SUIT protocol pattern: 1GM;2D;2c;3S;4U;5Rot-

The SUIT-011 protocols are designed to study physiologically relevant maximum mitochondrial respiratory capacity (OXPHOS with NS substrates) and coupling/pathway control states. SUIT-011 gives information of the linear coupling control (L- P) with NADH linked-substrates (GM). GM and PM yield practically identical fluxes in human skeletal muscle fibres. However, PM is the superior alternative to GM, since the fractions of the N-pathway is lower and of the S-pathway is higher with GM compared to PM. PM, therefore, yields a more sensitive assay for the diagnosis of injuries in the N-linked pathway (compare SUIT-001 and SUIT-004). Moreover, SUIT-011 allows the evaluation of the coupling-control state (P- E) with NADH and succinate linked-substrates (NS) and the pathway control in OXPHOS (NS) and ET state (NS and S). SUIT-011 can be extended with the CIV assay module.


Communicated by Doerrier C and Gnaiger E (last update 2019-06-05)

Specific SUIT protocols

1GM;2D;2c;3S;4U;5Rot;6Ama.png D024 O2 traces.png

MitoPedia: SUIT

Steps and respiratory states

SUIT-011

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1GM GML(n) N CI 1GM
2D GMP N CI 1GM;2D
2c GMcP N CI 1GM;2D;2c
3S GMSP NS CI&II 1GM;2D;2c;3S
4U GMSE NS CI&II 1GM;2D;2c;3S;4U
5Rot SE S CII 1GM;2D;2c;3S;4U;5Rot
6Ama ROX 1GM;2D;2c;3S;4U;5Rot;6Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB


Questions.jpg


Click to expand or collaps
Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>

Strengths and limitations

  • Comparison of GM- with PM-capacity yields important information on N-pathway respiratory control upstream of CI (Lemieux et al. 2017; Votion et al. 2012).
  • A succinate concentration of >10 mM may be required for saturating SE capacity.
  • Rox might be inhibited slightly further by inhibition of CIV by cyanide (KCN; 1 ΞΌM). But cyanide inhibits not only CIV, but also catalase and other oxygenases involved in ROX.
+ NS-OXPHOS capacity provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
+ Glutamate is easier to prepare compared to pyruvate.
+ Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
+ Reasonable duration of the experiment.
- GM and PM yield typically identical fluxes in human skeletal muscle fibres. However, PM is the superior alternative to GM: the fraction of the N-pathway is lower and of the S-pathway is higher with GM compared to PM (GMP is inhibited by the CII inhibitor malonic acid to a larger extent than PMP). PM, therefore, yields a more sensitive assay for the diagnosis of injuries in the N-pathway, since an impairment of N-pathway capacity can be compensated partially by activation of the S-pathway. This is a disadvantage compared to SUIT-004 and SUIT-008 for diagnosis of N-capacity.
- To detect an additive effect of P after GMP, pyruvate would have to be added as step 3 (before S). However, inhibition of respiration was observed after titration of P (5 mM) in horse skeletal muscle fibres (Votion et al 2012), which was not the case when P was titrated in steps of 1 mM.
- When evaluating the additive effect of the N- and S-pathway, it has to be considered that NSP- and NSE-capacities can only be compared with NP- and SE-capacities. This is not a problem when NSP = NSE (Gnaiger 2009). Otherwise, it may be assumed that SP = SE (Votion et al 2012), such that NSP can be compared with NP + SP. SUIT-004 should be chosen for the additive effect in the ET-state.
- Rox may be lower in substrate states earlier in the SUIT protocol. Therefore, this Rox measurement is frequently taken as a methodological control rather than as the final basis of Rox correction of mitochondrial respiration (mt).
- Careful washing is required after the experiment to avoid carry-over of inhibitors and uncoupler.
- CIV activity is not measured, to save experimental time.


Compare SUIT protocols

  • GM and PM yield typically identical fluxes in human skeletal muscle fibres.
  • SUIT-004 1PM;2D;3U;4S;5Rot-: SUIT-004 allows the evaluation of the linear coupling control (L- P) with PM (instead of GM) as NADH linked-substrates. Moreover, in SUIT-004 the linear coupling control from P to E (with PM) and the ET-pathway state in NS- and S-pathways can be assessed.
  • SUIT-008 1PM;2D;3G;4S;5U;6Rot-: SUIT-008 protocols are designed to assess the additivity between the N- and S-pathway in the Q-junction, providing a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
  • SUIT-001 1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-: SUIT reference protocol 1 (RP1)gives information of the linear coupling control (L- P- E) with NADH linked-substrates (PM). Moreover, the pathway control in ET state (N, NS, FNS, S and SGp pathways) can be evaluated by using this SUIT protocol.
  • SUIT-028: PGM as NADH linked-substrates.

References

MitoPedia concepts: MiP concept, SUIT protocol, Recommended 


MitoPedia methods: Respirometry